Galapagos NV (NASDAQ:GLPG)‘s stock had its “buy” rating restated by equities research analysts at Cowen and Company in a research report issued to clients and investors on Thursday.
Several other brokerages also recently weighed in on GLPG. Janney Montgomery Scott downgraded Galapagos NV from a “buy” rating to a “sell” rating in a report on Monday, April 24th. BidaskClub downgraded Galapagos NV from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Nomura cut their price target on Galapagos NV from $108.00 to $121.00 and set a “buy” rating for the company in a report on Thursday, June 22nd. Stifel Nicolaus boosted their price target on Galapagos NV from $65.00 to $83.00 and gave the company a “hold” rating in a report on Monday, May 1st. Finally, Zacks Investment Research downgraded Galapagos NV from a “buy” rating to a “hold” rating in a report on Monday, April 24th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $96.14.
Galapagos NV (NASDAQ GLPG) opened at 83.73 on Thursday. Galapagos NV has a 52-week low of $52.50 and a 52-week high of $94.88.
TRADEMARK VIOLATION WARNING: “Galapagos NV (GLPG) Stock Rating Reaffirmed by Cowen and Company” was originally posted by Stock Observer and is owned by of Stock Observer. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://www.thestockobserver.com/2017/08/12/galapagos-nv-glpg-stock-rating-reaffirmed-by-cowen-and-company.html.
Several hedge funds have recently added to or reduced their stakes in GLPG. Tower Research Capital LLC TRC purchased a new stake in Galapagos NV during the first quarter worth approximately $161,000. Acadian Asset Management LLC purchased a new stake in Galapagos NV during the second quarter worth approximately $166,000. New York State Common Retirement Fund purchased a new stake in Galapagos NV during the second quarter worth approximately $166,000. Bank of Montreal Can increased its stake in Galapagos NV by 8,736.4% in the first quarter. Bank of Montreal Can now owns 1,944 shares of the biotechnology company’s stock worth $168,000 after buying an additional 1,922 shares during the last quarter. Finally, Pacad Investment Ltd. purchased a new stake in Galapagos NV during the second quarter worth approximately $168,000. Institutional investors and hedge funds own 19.99% of the company’s stock.
Galapagos NV Company Profile
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with MarketBeat.com's FREE daily email newsletter.